SUNNYVALE, CA–(March 19, 2009) – Arrayit Corporation (OTCBB: ARYC), a leader of proprietary life science technologies founded on the Company’s vast microarray technology products, announced today that the final steps of the business combination with Integrated Media Holdings, Inc. has been completed, and thus will begin trading on the OTC Bulletin Boards as “ARYC” effective Thursday, March 19, 2009.

“This symbol approval concludes a long process of going public, and we are very pleased to have completed the final step in our move to enter the public arena and prepare to obtain capital for rapid expansion of our existing product line. With ARYC as our new ticker symbol, we can now better leverage our Company’s intellectual properties in the public markets to further Arrayit’s business objectives,” stated Ms. Rene Schena, Chief Executive Officer. “Our move from being privately held to a publicly held company has also resulted in us re-domiciling, as well as completing a reverse split of our common stock,” she continued.

Arrayit Corporation, formerly Integrated Media Holdings, Inc., has completed approval to change the name of the entity, re-domiciling to Nevada from Delaware, and completing a reverse stock split of one for 30 shares.

About Arrayit Corporation

Arrayit Corporation, headquartered in Sunnyvale, California, leads and empowers the genetic, research, pharmaceutical, and diagnostic communities through the discovery, development and manufacture of proprietary life science technologies and consumables for disease prevention, treatment and cure. It now offers over 650 products to a customer base of more than 2,500 laboratories worldwide, including most every major university, pharmaceutical and biotech company, major agricultural and chemical company, government agency, national research foundation and many private sector enterprises. Please visit www.arrayit.com for more information.

Safe Harbor Statement

Except for historical information contained herein, statements made in this release that would constitute forward-looking statements may involve certain risks and uncertainties. All forward-looking statements made in this release are based on currently available information and the Company assumes no responsibility to update any such forward-looking statement. The following factors, among others, may cause actual results to differ materially from the results suggested in the forward-looking statements. The factors include, but are not limited to, risks that may result from changes in the Company’s business operations; our ability to keep pace with technological advances; significant competition in the biomedical business; our relationships with key suppliers and customers; quality and consumer acceptance of newly introduced products; market volatility; non-availability of product; excess inventory; price and product competition; new product introductions, the outcome of our legal disputes; the possibility that the review of our prior filings by the SEC may result in changes to our financial statements; and the possibility that stockholders or regulatory authorities may initiate proceedings against Arrayit and/or our officers and directors as a result of any restatements. Risk factors associated with our business, including some of the facts set forth herein, are detailed in the Company’s Form 10-K for the fiscal year ended December 31, 2007 and Form 10-Q/A for the fiscal first quarter ended March 31, 2008 and Form 10-Q for the fiscal second quarter ended June 30, 2008.